The Foundation’s goal is to work with a diverse group of physicians, organizations, industry partners, individuals, patients, survivors, and their families to identify solutions and make timely and meaningful change and turn lung cancer into a chronically managed disease by 2023. Patients fighting Lung Cancer today and those who will be diagnosed tomorrow are at the heart of their mission. Driven by the knowledge that Lung Cancer is the number one cancer killer worldwide annually, their imperative is to dramatically increase patient survival rate. Their ultimate goal is to be the global leader fighting Lung Cancer and the largest source of non-profit funding dedicated to turning Lung Cancer into a manageable, chronic disease and ultimately, a curable disease.

The Addario Lung Cancer Medical Institute (ALCMI, voiced as “Alchemy”) works in tandem with their partner, the Addario Lung Cancer Foundation (ALCF).  ALCMI is patient founded, focused, and funded.  

Since its founding in 2006, the ALCF has grown into the first international collaborative entity of its kind, raising over $30 million for Lung Cancer research through a variety of fundraising campaigns and initiatives.  ALCMI was founded 2 years later in 2008.

Patients benefit by being empowered through more active involvement and participation in advancing discovery, treatment and care for themselves and others. By participating in clinical research and giving researchers access to their biospecimens, clinical data, and therapeutic outcomes, patients will help to accelerate the development of precision medicine for lung cancer.